The Journal of Urology
Volume 181, Issue 4 , Pages 1658-1664 , April 2009

Prostogram Predicted Brachytherapy Outcomes are Not Universally Accurate: An Analysis Based on the M. D. Anderson Cancer Center Experience With 125Iodine Brachytherapy

  • Steven J. Frank

      Affiliations

    • Department of Radiation Oncology, University of Texas M. D. Anderson Cancer Center, Houston, Texas
    • Corresponding Author InformationCorrespondence: 1515 Holcombe Blvd., Unit 97, Houston, Texas 77030 (telephone: 713-563-2364; FAX: 713-563-2366)
    • ,
  • Lawrence B. Levy

      Affiliations

    • Department of Radiation Oncology, University of Texas M. D. Anderson Cancer Center, Houston, Texas
    • ,
  • Deborah A. Kuban

      Affiliations

    • Department of Radiation Oncology, University of Texas M. D. Anderson Cancer Center, Houston, Texas
    • Financial interest and/or other relationship with Calypso Medical and Amgen.
    • ,
  • Andrew K. Lee

      Affiliations

    • Department of Radiation Oncology, University of Texas M. D. Anderson Cancer Center, Houston, Texas
    • ,
  • Rajat J. Kudchadker

      Affiliations

    • Department of Radiation Physics, University of Texas M. D. Anderson Cancer Center, Houston, Texas
    • ,
  • Teresa L. Bruno

      Affiliations

    • Department of Radiation Oncology, University of Texas M. D. Anderson Cancer Center, Houston, Texas
    • ,
  • Marco van Vulpen

      Affiliations

    • Department of Radiation Oncology, Utrecht University Medical Center, Utrecht, The Netherlands
    • ,
  • David A. Swanson

      Affiliations

    • Department of Urology, University of Texas M. D. Anderson Cancer Center, Houston, Texas

Received 8 August 2008

References 

  1. Kattan MW, Potters L, Blasko JC, Beyer DC, Fearn P, Cavanaugh W, et al. Pretreatment nomogram for predicting freedom from recurrence after permanent prostate brachytherapy in prostate cancer. Urology. 2001;58:393
  2. Prostogram. http://www.mskcc.org/mskcc/html/10088.cfmAccessed May 15, 2008
  3. Frank SJ, Kuban DK, Lee AK, Levy LB, Kudchadker R, Bruno T, et al. Prostate brachytherapy—the M. D. Anderson Cancer Center experience. J Urol. 2008;179:396
  4. Harrell FE. Regression Modeling Strategies. New York: Springer-Verlag New York; 2006;
  5. Hermansen SW: Evaluating predictive models: computing and interpreting the c statistic. Presented at Data Mining and Predictive Modeling, SAS Global Forum 2008, San Antonio, Texas, March 16-19, 2008, paper 143.
  6. Frank SJ, Pisters LL, Davis J, Lee AK, Bassett R, Kuban DA. An assessment of quality of life following radical prostatectomy, high dose external beam radiation therapy and brachytherapy iodine implantation as monotherapies for localized prostate cancer. J Urol. 2007;177:2151
  7. Sanda MG, Dunn RL, Michalski J, Sandler HM, Northouse L, Hembroff L, et al. Quality of life and satisfaction with outcome among prostate-cancer survivors. N Engl J Med. 2008;358:1250
  8. D'Amico AV, Whittington R, Malkowicz SB, Schultz D, Blank K, Broderick GA, et al. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA. 1998;280:969
  9. Blasko JC, Grimm P, Sylvester J, Badiozamani KR, Hoak D, Cavanagh W. Palladium-103 brachytherapy for prostate carcinoma. Int J Radiat Oncol Biol Phys. 2000;46:839
  10. Stone NN, Stock RG, Unger P. Intermediate term biochemical-free progression and local control following 125Iodine brachytherapy for prostate cancer. J Urol. 2005;173:803
  11. DI Blasio CJ, Rhee AC, Cho D, Scardino PT, Kattan MW. Predicting clinical end points: treatment nomograms in prostate cancer. Semin Oncol. 2003;30:567
  12. Stock RG, Stone NN, Tabert A, Iannuzzi C, DeWyngaert J. A dose-response study for I-125 prostate implants. Int J Radiat Oncol Biol Phys. 1998;41:101
  13. Ash D, Al-Qaisieh B, Bottomley D, Carey B, Joseph J. The correlation between D90 and outcome for I-125 seed implant monotherapy for localized prostate cancer. Radiother Oncol. 2006;79:185
  14. Kattan MW, Stock RG, Ciezki JP, Davis BJ, Zelefsky MJ, Roach M, et al. An updated 9-year preoperative nomogram predicting for prostate cancer recurrence after permanent prostate brachytherapy. Proc 48th Annual ASTRO Meeting. 2007;104:S59
  15. Vira MA, Tomaszewski JE, Hwang WE, D'Amico AV, Whittington R, Vanarsdalen K, et al. Impact of the percentage of positive biopsy cores on the further stratification of primary grade 3 and grade 4 Gleason score 7 tumors in radical prostatectomy patients. Urology. 2005;66:1015
  16. Patel AA, Chen MH, Renshaw AA, D'Amico AV. PSA failure following definitive treatment of prostate cancer having biopsy Gleason score 7 with tertiary grade 5. JAMA. 2007;298:1533
  17. Frank SJ, Grimm PD, Sylvester JE, Merrick GS, Davis BJ, Zietman A, et al. Interstitial implant alone or in combination with external beam radiation therapy for intermediate-risk prostate cancer: a survey of practice patterns in the United States. Brachytherapy. 2007;6:2
  18. Zelefsky MJ. PSA bounce versus biochemical failure following prostate brachytherapy. Nat Clin Pract Urol. 2006;3:578
  19. Horwitz EM, Levy LB, Thames HD, Kupelian PA, Martinez AA, Michaliski JM, et al. Biochemical and clinical significance of the post treatment prostate-specific antigen bounce for prostate cancer patients treated with external beam radiation therapy alone: a multi-institutional pooled analysis. Cancer. 2006;107:1496

 Study received M. D. Anderson Cancer Center institutional review board approval.

PII: S0022-5347(08)03264-3

doi: 10.1016/j.juro.2008.11.101

The Journal of Urology
Volume 181, Issue 4 , Pages 1658-1664 , April 2009

Article Tools

* Image Usage & Resolution